FDA corrects patent extension review periods for six drugs
The FDA corrects the length of the regulatory review period for ANDEMBRY, ANZUPGO, ANKTIVA, BIZENGRI, BRINSUPRI, and DAYVIGO due to calculation errors. The corrections apply to determinations announced on August 10, August 17, and September 9, 2026; no other changes are made.
Primary source
Federal Register notice, October 23, 2026
Determination of Regulatory Review Period for Purposes of Patent Extension; Correction of Notices-ANDEMBRY; ANZUPGO; ANKTIVA; BIZENGRI; BRINSUPRI; DAYVIGO
Read the source: Determination of Regulatory Review Period for Purposes of Patent Extension; Correction of Notices-ANDEMBRY; ANZUPGO; ANKTIVA; BIZENGRI; BRINSUPRI; DAYVIGO federalregister.gov
Machine-summarized from the source above; not independently reported. How we use automation